European Society for Medical Oncology (ESMO)

The European Society for Medical Oncology (ESMO) is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 150 countries worldwide, ESMO was founded in 1975.

Nivolumab versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients with Platinum-Resistant Ovarian Cancer: The NINJA Trial

ESMO 2020

A phase 3 study comparing nivolumab to treatment with gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer revealed similar overall survival and response rates between the 2 groups. Nivolumab was better tolerated than gemcitabine/pegylated liposomal doxorubicin, with fewer all-grade and grade 3/4 adverse events. Read More ›

Adjuvant Innovative Peptide Vaccine Therapy Shows Promising Activity in Early-Stage Triple Negative Breast Cancer

ESMO 2018 – Wrap-up

A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer. Read More ›

Efficacy and Safety of Front-Line Veliparib and Paclitaxel Weekly versus Every 3 Weeks in the VELIA Study

ESMO 2020

In patients with newly diagnosed high-grade serous ovarian cancer, dose-dense weekly paclitaxel was associated with longer progression-free survival and higher frequency of grade 3/4 adverse events, including hematologic toxicities, versus paclitaxel given every 3 weeks. Read More ›

Timing of Adverse Events During Maintenance Treatment with Rucaparib for Recurrent Ovarian Cancer in Phase 3 Study

ESMO 2020

The phase 3 ARIEL3 study investigated rucaparib as maintenance therapy in patients with recurrent ovarian cancer. An exploratory safety analysis found time to onset of nonhematologic treatment-emergent adverse events was 1 month, 2 months for anemia, and 3 months for decreased hemoglobin. Read More ›

Response to Olaparib Monotherapy in Relapsed Ovarian Cancer by HRR Gene Mutational Status and HRD Scarring Analysis

ESMO 2020

A phase 2, randomized study of patients with platinum-resistant relapsed ovarian cancer assessed overall response to olaparib monotherapy compared with standard-of-care chemotherapy. Olaparib was effective in platinum-resistant and platinum-sensitive patients with and without homologous recombination repair (HRR) gene alterations. Read More ›

Olaparib Maintenance Therapy in Clinical Practice: Quality-of-Life Interim Results of the C-PATROL Study in Ovarian Cancer

ESMO 2020

An observational study of hospitalized patients and patients in outpatient treatment facilities being treated with olaparib as maintenance therapy for relapsed BRCA-mutated ovarian cancer following platinum-based chemotherapy reveals preservation of health-related quality of life in interim study results. Read More ›

Efficacy and Safety of Niraparib in Older Patients with Advanced Ovarian Cancer from PRIMA/ENGOT-OV26/GOG-3012

ESMO 2020

In patients with advanced ovarian cancer, niraparib resulted in similar efficacy, safety, and quality-of-life outcomes for patients 65 years of age and those ≥65 years of age. An individualized starting dose resulted in fewer grade ≥3 thrombocytopenia events than a fixed starting dose. Read More ›

Phase 2 Trial of Olvi-Vec in Heavily Pretreated Platinum-Resistant/Refractory Ovarian Cancer

ESMO 2020

The VIRO-15 trial of intraperitoneal Olvi-Vec virus infusion followed by intravenous carboplatin-doublet ± bevacizumab in pretreated platinum-resistant/refractory ovarian cancer patients revealed promising response rates and progression-free survival. Safety results were consistent with a previous phase 1b trial of this agent. Read More ›

Olaparib + Durvalumab and Bevacizumab: Initial Results in Patients with Non-Germline BRCA-Mutated Platinum-Sensitive Relapsed Ovarian Cancer

ESMO 2020

For patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer, the triple combination of olaparib, durvalumab, and bevacizumab demonstrated a promising 24-week disease control rate and safety profile while the combination of olaparib plus durvalumab did not meet the prespecified efficacy target. Read More ›

Results of 5-Year Follow-Up of Maintenance Olaparib in Patients with Newly Diagnosed, Advanced Ovarian Cancer

ESMO 2020

The SOLO1 trial studied maintenance olaparib in newly diagnosed patients with advanced BRCA-mutated ovarian cancer. This analysis assesses outcomes 5 years after the last patient enrolled in the trial and represents the longest follow-up for a PARP inhibitor trial in this setting. Read More ›

European Society for Medical Oncology (ESMO)

Page 1 of 9